About - Mediwound

"At MediWound, our talented team of professionals transform great ideas into reality. Our goal is to elevate the standard of care for our patients, resulting in a much better quality of life"

Ofer Gonen

Chief Executive Officer

Ofer Gonen joined MediWound’s leadership team as Chief Executive Officer in July 2022, bringing more than 20 years of experience in managing global life science companies. Prior to his CEO appointment, Mr. Gonen served as CEO of Clal Biotechnology Industries Ltd. (TASE: CBI), Israel’s leading life science investment company, as well as a managing partner at the Anatomy Medical Technologies Fund. Mr. Gonen served as the General Manager of Biomedical Investments Ltd., a managing partner at Arte Venture Group, and held a variety of executive positions in the industry. In addition, Mr. Gonen founded Cactus Acquisition Corp. 1 (Nasdaq: CCTS), focused on healthcare companies. Mr. Gonen held board member positions at several private and publicly traded companies, including Gamida Cell (Nasdaq: GMDA), Cactus (Nasdaq: CCTS), Anchiano Therapeutics (Nasdaq: ANCN), MediWound (Nasdaq: MDWD), Polyheal, Elicio Therapeutics and eXIthera Pharmaceuticals. Mr. Gonen received a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction. He graduated the prestigious “Talpiot” program of the Israeli Defense Forces.

“It is a privilege to take on this role during such an exciting and transformative time for MediWound. I look forward to working with this outstanding management team as we focus our efforts on advancing our clinical pipeline. I am excited to be part of a company that will meaningfully improve the lives of millions of patients worldwide.”

Robert J. Snyder

Chief Medical Officer

Dr. Robert J. Snyder (DPM, MSc, MBA, CWSP, FFPM RCPS) is Dean, Professor, Director of Clinical Research and Fellowship Director in Wound Care and Research at Barry University School of Podiatric Medicine. He is certified in foot and ankle surgery by the American Board of Podiatric Surgery and is also a board-certified wound specialist. Dr. Snyder is past-president of the Association for the Advancement of Wound Care and past-president of the American Board of Wound Management. Dr. Snyder has completed an MBA in Health Management from The George Washington University and the Global Clinical Scholars Research Training Program at Harvard Medical School. Dr. Snyder is a key opinion leader and sought-after speaker, lecturing extensively throughout the United States and abroad. He has published several book chapters and over 165 papers in peer reviewed and trade journals on wound care, and was the recipient of the Dr. Robert Warriner Memorial Award for excellence in wound management. Dr. Snyder serves as the Associate Editor for JAPMA and on the editorial advisory boards of Ostomy Wound Management, Wounds and as a periodic reviewer for the Lancet and NEJM. He has been a Principal Investigator on more than 65 randomized controlled trials for innovative wound healing modalities and products.

"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"

Lior Rosenberg

Founder & Medical Director

Lior is one of our co‑founders and has served as our Chief Medical Technology Officer since 2001 and served as a member of our board of directors from 2001 to 2013. Since 2001, Dr. Rosenberg has headed the unit for Cleft Lip Palate and Craniofacial Deformities at Soroka University Medical Center and Meir Medical Centers in Beer Sheva and Kfar Saba, Israel, respectively. Since 1987, he has served as a Full Professor of plastic surgery at the Ben‑Gurion University Medical School in Beer Sheva, Israel. He also serves as the Chairman of the Burn Disaster Committee for the International Society of Burn Injuries and the Israeli Ministry of Health. From 1987 to 2012, Dr. Rosenberg served as the chairman of the Department of Plastic Surgery and Burn Unit at Soroka University Medical Center in Beer Sheva, Israel. He is a founding member of the Israeli Burn Association and the Mediterranean Burn Council, a member of the American Burn Association and a national representative at the European Burn Association. Dr. Rosenberg holds a M.D. degree from Tel‑Aviv University, Israel and a Professor of Plastic Surgery degree from the Ben Gurion University, Israel.

"At MediWound, science, technological innovation and deep industry knowledge expands our portfolio with new bio-therapeutic solutions for unmet medical needs"

Ety Klinger

Chief R&D Officer

Ety has served as our Chief Research and Development Officer since May 2014. Prior to joining MediWound, Dr. Klinger was Vice President of Research and Development at Proteologics Ltd since July 2011, where she was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva. Prior to this, Dr. Klinger served for 17 years in numerous leadership positions at Teva’s global innovative R&D division and served as Teva’s Board representative at various biotechnology companies. Dr. Klinger was a key member of the Copaxone® development team. As a project leader she led the chemistry, manufacture and control, preclinical, clinical and post‑marketing R&D activities of various innovative treatments for multiple sclerosis (MS), autoimmune and neurological diseases. From 2006 to 2011, as a Senior Director at Teva, Dr. Klinger was a member of Teva’s global innovative R&D management team. From 2006 to 2008, she served as the Head of MS and Autoimmune Diseases at Teva, and led the Life Cycle Management (LCM) of innovative R&D. Dr. Klinger holds a B.Sc. in Biology from the Hebrew University in Jerusalem, a M.S. and a Ph.D. in Biochemistry from Tel‑Aviv University and an MBA degree from Tel Aviv University and Northwestern University.

Tzvi Palash

Chief Operating Officer

Tzvi Palash joins MediWound as Chief Operating Officer in July 2022 from Enlivex, where he leads the design and construction of the new cGMP manufacturing facility. Tzvi brings over 35 years of experience with notable expertise in commercial operations in the healthcare industry. Prior to this, he served as COO at Gamida Cell, where he directed all operational activities towards its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for omidubicel. Mr. Palash was COO at Protalix Biotherapeutics, where he led all operational activities through the company’s FDA approval of Elelyso^®. Prior to Protalix, Mr. Palash was a General Manager at ColBar LifeScience, a biomaterial company acquired by Johnson & Johnson, where he led the planning, construction, scale-up and regulatory oversight of its Israel-based manufacturing facility. He also successfully led FDA audits for Evolence^® and Ossix^® and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Mr. Palash held operational roles at Teva Pharmaceutical Industries and Interpham Laboratories.

"In MediWound, we harness innovation, commitment, dedication and determination to change treatment paradigms to help patients’ in their times of pain. To see their relief is the most rewarding thing for us to cherish. It keeps driving us every single day"

Boaz Gur-Lavie

Chief Financial Officer

Boaz has served as our Chief Financial Officer since June 2019. Prior to joining MediWound, Mr. Gur-Lavie co-founded in 2015 the Center for Digital Innovation (CDI), a non-profit organization determined to improve the quality of lives by creating innovative new solutions for challenges in the space of healthy aging and digital health, while focusing on senior citizens. In early 2015, he also co-founded MDClone, which introduced the world’s first Healthcare Data Sandbox, unlocking healthcare data to enable exploration, discovery and collaboration. Previously, he served as the chief financial officer of the Nasdaq-listed company, Pluristem Therapeutics, a stem-cell development company, from 2013 to 2015. He also served as the chief financial officer of STARLIMS, a Nasdaq listed company, until it was acquired by Abbott Laboratories in 2010, after which he served as the chief financial officer of Abbott’s informatics division until 2013. Mr. Gur-Lavie is a certified public accountant and received his B.A. in economics and M.B.A. in finance from the Ben-Gurion University in Israel.

"Creativity is thinking up new things. Innovation is doing new thing. At MediWound, we are privileged to have both, allowing us to improve our patients' lives and the standard of care."

Yaron Meyer

Executive Vice President & General Counsel

Yaron has served as our Executive Vice President since March 2019 and as our General Counsel and Corporate Secretary since December 2013. From April 2008 to November 2013, he served as the Corporate Secretary of Clal Biotechnology Industries Ltd. (CBI). From November 2010 to November 2013, he served as the General Counsel and Corporate Secretary of D‑Pharm Ltd. From April 2008 to May 2010, he served as a legal counsel of Clal Industries Ltd. From May 2005 to April 2008, he worked as an associate at Shibolet & Co. Advocates. Mr. Meyer is a member of the Israel Bar Association and holds an LL.B. degree from Haifa University, Israel.

"Establishing a state of the art cGMP sterile facility that takes the pineapple stem and makes it a pharmaceutical drug is a life accomplishment"

Andrey Kon

VP Plant Manager

Andey has served as our VP Plant Manager since 2008 and as our head of production since MediWound's inception in 2001. Mr. Kon has over 20 years of experience in the biotech industry. Prior to joining MediWound he served as head of production of Omrix pharmaceuticals Inc. Mr. Kon holds a M.Sc. in Biotechnology from St. Petersburg pharmaceutical institute.

“Clinical trials are important for discovering new treatments for diseases, as well as new ways to detect, diagnose, and reduce the chance of developing diseases. I’m proud to be part of all discoveries achieved in the last 20 years in the clinical development of our products and having new therapies available to patients”

Keren David-Zarbiv

VP Clinical Affairs

Keren has served as our VP Clinical Affairs since 2019 and as MediWound’s Director of Clinical Affairs since March 2013. Ms. David-Zarbiv. Ms. David holds a B.Sc. and M.Sc. with distinction from the Faculty of Biotechnology and Food Eengineering from the Technion -Israel Institute of Technology.

"I have the privilege to work to grow and develop with the company throughout the years, from a small startup to an established publicly traded company. The level of professional, commitment and high excellence of the company together with the way we improve patients’ lives is what drives me"

Roni Solomon

VP Finance

Roni has served as our VP Finance since 2019 and as our contoller since November 2006. Prior to joining MediWound, she served in several financial positions in private companies. Ms. Solomon has vast experience in accounting, budgeting and financial planning & control. Ms. Solomon holds a B.Sc. in Business Administration from the Business Management College, Israel and a MBA from NYU Polytechnic School of Engineering, New-York.

"Deep and robust foundations, are the key to every solid building. I am proud to lead the pre-clinical as well as the Chemistry, Manufacturing and Controls (CMC) development at MediWound. By a team work, my group is establishing the foundations for turning vision to reality"

Eilon Asculai

VP R&D

Eilon has served as our VP R&D since July 2007. Prior to joining Mediwound, Dr. Asculai was the Senior Director of the Pharmaceutical R&D at Perrigo Israel Pharmaceuticals. In this position, he managed all pharmaceutical development activities from initiation to submission. Dr. Asculai led a considerable senior scientific and technical staff in the process of development of generic and innovative products. During his service at Perrigo, the pharmaceutical R&D specialized mainly in topical and dermatological products and became one of the world’s leading R&D groups in this field. Prior to his last position, Dr. Asculai served for nine years, in various management positions in Perrigo in Pharmaceutical R&D. Dr. Asculai holds B.Sc., M.Sc. (Summa cum Laude), Ph.D in Medical Sciences, and MBA (hons.) degrees, all from the Ben-Gurion University

"Regulatory affairs are the final stamp for our products and we are keen to maintain it at the highest standards. I’m proud of the experience, knowhow and knowledge we have acquired in the last 20 years, working with all major health authorities and bringing NexoBrid to the burn patients"

Smadar Nestor

VP Regulatory Affairs

Smadar has served as our VP Regulatory Affairs since 2019 ans as our Director of Regulatory Affairs since January 2008. Ms. Nestor has vast experience in the field of international regulatory affairs. Prior to joining MediWound, she was responsible for the planning and coordinating of key regulatory activities in the pharmaceutical industry while working for CollgardBiopahrmaceuticals Ltd. as a Regulatory Affairs Manager and for Teva Pharmaceutical Industries Ltd as a Regulatory Affairs Product Manager. Ms. Nestor holds a B.Sc. in Pharmacy from the Hebrew University of Jerusalemand a M.Sc., with distinction, in Human Genetics from the Faculty of Medicine, Tel Aviv University, Israel.

"Quality is a crucial component of becoming an excellent organization. It is what enable us to provide the value with assuring the quality of our products and the safeness of our patients"

Nimrod Leuw

VP Quality

Nimrod has serves as our VP Quality since 2019 and as our Director of Quality Assurance & Controlsince November 2007. Mr. Leuw has over 20 years of experience in the field of quality in the pharmaceutical and biotechnology industry. Prior to joining MediWound, he served for 3 years as Director of Quality Assurance & Control at Prochon Biotech company and for 11 years at Teva Pharmaceutical Industries Ltd where he served in several positions in Quality Assurance. Mr. Leuw holds a B.Sc. in Chemistry from Ben Gurion University, Israel

Nachum (Homi) Shamir

Chairman of the Board of Directors

Nachum "Homi" Shamir serves as Chairman of our Board of Directors since August 2022 with a proven track record of bringing game-changing technologies to the market. He most recently served as Chairman, President, CEO of Luminex Corporation (LMNX) prior to its acquisition in 2021 by DiaSorin for $1.8 billion. Additionally, Mr. Shamir has served as President and CEO at Given Imaging (GIVN) from 2006 through its sale in 2014 to Covidien PLC (now Medtronic) for $1 billion. Prior to that, he was Corporate Vice President of Eastman Kodak and President of Eastman Kodak Transaction and Industrial Solutions Group. Mr. Shamir joined Eastman Kodak from Scitex Corporation where he held various executive positions, including President and CEO, prior to its acquisition in 2004 by Eastman Kodak for $262 million. Mr. Shamir has held senior management positions at various international companies, mainly in the Asia Pacific regions. He currently serves on the Board of Directors of IsoPlexis (ISO); and as a Board Member at Strata Skin Sciences (SSKN) and Chairman of the Board at Cactus Acquisition Corp. (CCTS). His previous Board appointments include Cogentix Medical (CGNT), which was acquired in 2018 by Laborie Medical Technologies for $214 million, and Invendo Medical GmbH, which was acquired in 2017 by Ambu for €225 million. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Stephen T. Wills

Board Member

Steve has served as a member of our board of directors since May 2017 and as Chairman of our board since October 2017 until August 2022. since August 2022 Steve serves as a member of our board of directors. Mr. Wills has served, since 1997, as the Executive Vice President, Secretary, Treasurer and Chief Financial Officer of Palatin Technologies, Inc. ("Palatin"), a publicly‑held biopharmaceutical company developing targeted, receptor‑specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. He has served in various roles at Palatin since 2017, including as Executive Vice President of Operations from 2005 until June 2011 and as and as Chief Operating Officer and Executive Vice President from 2011 to present. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc. ("Derma"), a publicly‑held company providing advanced wound care products, from December 2015 until February 2017 when Derma was acquired by Integra Lifesciences Holdings Corporation. Mr. Wills also served as the lead director and chairman of the audit committee until February 2017 and as Derma Chief Financial Officer from 1997 to 2000. Mr. Wills serves on the board of trustees and executive committee of The Hun School of Princeton since 2013, and its chairman since June 2018. From 1991 to 2000 Mr. Wills was the president and Chief Operating Officer of Golomb, Wills & Company, P.C., a public accounting firm. Mr. Wills, a certified public accountant, received his B.S in accounting from West Chester University, and a M.S. in taxation from Temple University.

Vickie R Driver

Board Member

Vickie has served as a member of our board of directors since May 2017. Dr. Driver is board certified in foot surgery by the American Board of Podiatric Surgery and is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Rhode Island and Massachusetts. Her career as a podiatric physician and surgeon has included a special emphasis on limb preservation and wound healing in her medical practice, as well as, research and education. Dr. Driver was Professor of Surgery in the Department of Orthopedics at Brown University (Clinical) from 2014 to 2019 and is now Adjunct Professor of Barry University and Visiting Professor at Cardiff University. She has served for 11 years on the Board of Directors for the Association for the Advancement of Wound Care (“AAWC”), and recently completed her tenure as President for this international organization. Dr. Driver is also the chair of Wound Care Experts and U.S. Food and Drug Administration (“FDA”) Clinical Endpoints Project. She also serves as a member at large to the Board of Directors of the Wound Healing Society (“WHS”) and Board Member to the Critical Limb Ischemia (“CLI”) Global Society. In addition, she serves on multiple national and international clinical committees that focus on preventing limb loss and improving wound healing in the high‑risk population. She has served as an investigator for more than 70 important multi‑center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has served and chaired multiple committees for large national and international pivotal clinical trials and has authored over 120 publications and abstracts. Dr. Driver is credited with the development and directorship of multiple major multidisciplinary Limb Preservation – Wound Healing Centers of Excellence, including Military/VA, Hospital and University based programs. From 2015 to 2019, she has served as Director, Translational Medicine, Wound Healing at the Novartis Institute for Biomedical Research. From 2011 to 2014, she was Program Director, Inaugural Educational Committee at the American College of Wound Healing and Tissue Repair at University of Illinois School of Medicine. From 2011 to 2015, she was also Scientific Director, Colorado Prevention Center, Wound Care Laboratory at the University of Colorado. From 2012 to 2015, Dr. Driver held a number of positions at the Providence Veterans Administration Medical Center in Rhode Island, including Chief, Section of Podiatric Surgery and Director, Clinical Research, Limb Preservation and Wound Healing. Prior thereto, she held various positions at multiple major multidisciplinary Limb Preservation – Wound Healing Centers of Excellence. Dr. Driver received a Doctorate of Podiatric Medicine and Surgery from the California College of Podiatric Medicine and Surgery and a Masters in Medical Education from Samuel Merritt University.

Sharon Kochan

Board Member

Sharon has served as a member of our board of directors since June 2017. Mr. Kochan has served as Executive Vice President & President pharmaceuticals, for Perrigo Company Plc., a global, over‑the‑counter, consumer goods and specialty pharmaceutical company listed on the New York Stock Exchange, since 2018, President International from 2012 to 2018 and has been a member of the Perrigo Executive Committee since 2007. From March 2007 to July 2012, he served as Executive Vice President, General Manager of Prescription Pharmaceuticals for Perigo and from 2005 to 2007, he was Senior Vice President of Business Development and Strategy for Perrigo. Mr. Kochan was Vice President, Business Development of Agis Industries (1983) Ltd. from 2001 until Perrigo acquired Agis in 2005. He completed the Senior Management Program at the Technion Institute of Management in Haifa, Israel, received a Master of Science in Operations Research & Management Science from Columbia University in New York City and received a Bachelor of Science in Industrial and Management Engineering from Tel‑Aviv University in Tel‑Aviv, Israel.

Nissim Mashiach

Board Member

Nissim has served as a member of our board of directors since June 2017. Mr. Mashiach served as President and Chief Executive Officer of Macrocure Ltd., a Nasdaq‑listed biotechnology company focused on the treatment of chronic and other hard‑to‑heal wounds, from June 2012 to January 2017. From 2009 to 2012, he served as General Manager at Ethicon, a Johnson & Johnson company. Prior to Ethicon, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He holds an MBA from the University of Manchester in Manchester, England, an MPharmSc from the Hebrew University in Jerusalem, Israel, and a B.Sc, Chemical Engineering from the Technion‑Israel Institute of Technology in Haifa, Israel.

Assaf Segal

Board Member

Assaf has served as a member of our board of directors since October 2017. Mr. Segal has served as the Chief Financial Officer at Clal Biotechnology Industries Ltd. since July 2015. Mr. Segal serves as a board member of several companies, including FDNA Inc., Pi-Cardia Ltd., Biokine therapeutics Ltd., Campus Bio Ltd., Clal Life Sciences L.P. and Clal Application Center Ltd. Prior to that time, Mr. Segal was a Partner at Variance Economic Consulting Ltd., from 2004 until June 2015, where he provided in‑depth consulting for international and local clients in a wide range of industries, including telecommunications, internet, biotech, heavy industry and financial sectors. Previously, he founded a start‑up software company. Mr. Segal also previously held a managerial position at PriceWaterhouseCoopers Corporate Finance and was an Economic Department manager at the North American division of Amdocs Inc. His experience also includes risk management and house account (“Nostro”) trading at the Union Bank of Israel, and serving as an economist for capital markets in the Research Department of the Bank of Israel. Mr. Segal also has many years of experience in economic consulting and company valuations, joint ventures and financial instruments for investments, M&A, and IPOs. He has 15 years of experience in economic consulting for international and local clients in the Bio‑Tech sector as well as in Hi‑Tech, financial and other sectors. He holds a B.A. in Economics and Statistics and an M.B.A. (Finance and Information Systems) from the Hebrew University of Jerusalem.

David Fox

Board Member

David has served as a member of our board of directors since April 2020. Mr. Fox was most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee until 2019. Prior to joining Kirkland, Mr. Fox was partner with Skadden, Arps, Slate, Meagher & Flom LLP, where he was a member of its top governing committee. Mr. Fox is a director of Israel Discount Bank of New York, Gamida Cell Ltd., Atrium European Real Estate Limited, Atlas Crest Investment Corp. (which he is expected to leave upon closing of the merger between atlas crest and archer aviation) and Atlas Crest Investment Corp. II. He is a member of the board of directors at the Park Avenue Armory, and a member of the advisory board of New Alternatives for Children. Mr. Fox serves on the executive committee of the board of governors, and is an honorary fellow of the Hebrew University, Jerusalem. He holds an LL.B. degree from Jerusalem University, Israel.

Sharon Malka

Board Member

Sharon has served as a member of our board of directors since July 2022. Sharon served as our Chief Executive Officer since May 2019. Prior to that time, he served as our Chief Financial and Operations Officer, beginning in April 2007. From 2002 to 2007, Mr. Malka was a partner at Variance Economic Consulting Ltd., a multi‑disciplinary consulting boutique that specializes in financial and business services. Mr. Malka also served as a Senior Manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopers Global Network, from 1998 to 2002. Mr. Malka holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel.

Eric Shem-Tov

Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies

Recently collaborated with Nordic Capital in a deal valued at $1.3 billion. He also founded Biopharmax, a global design and construction provider of manufacturing facilities and systems for biotechnology, pharmaceutical and synthesis API manufacturers. Mr. Shem-Tov will provide MediWound with his expertise in scaling up facilities and optimizing manufacturing processes.

Samuel Moed

Venture Partner at aMoon, Israel’s largest HealthTech VC fund

Mr. Moed has recently retired from Bristol Myers Squibb (BMS), as Senior Vice President, Corporate Strategy. He led the strategic direction of the company with close linkage to all its major businesses, functions, and geographies. His recent focus was on the $90 billion acquisition and integration of Celgene by BMS. He serves in Board and advisory roles supporting companies in the HealthTech sector. Mr. Moed with his experience as an executive in the life sciences industry will provide MediWound with his expertise in strategic development for life science innovations.

John C. Lantis

Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon

He holds the academic title of Professor of Surgery at the Icahn School of Medicine. He is a world leader in limb salvage and lower extremity wound healing. To date, he has been the principal investigator on over 70 clinical trials. He directs a clinical research program in the field of lower extremity wound healing and tissue repair and published extensively. He currently sits on the editorial board of WOUNDS and is a reviewer for other journals. Dr. Lantis will provide MediWound with his medical expertise in all aspects of wound care.

Innovation Powers Us
Better Care Drives Us

Committed to Innovation
Dedicated to Improving Patients' Lives

Our People. Our Values. Our Culture

A Fully-Integrated Biopharmaceutical Company

RESEARCH & DEVELOPMENT

MANUFACTURING

Commercialization

Our People: Leading Change

Ofer Gonen

Robert J. Snyder

Lior Rosenberg

Ety Klinger

Tzvi Palash

Boaz Gur-Lavie

Yaron Meyer

Andrey Kon

Keren David-Zarbiv

Roni Solomon

Eilon Asculai

Smadar Nestor

Nimrod Leuw

Nachum (Homi) Shamir

Stephen T. Wills

Vickie R Driver

Sharon Kochan

Nissim Mashiach

Assaf Segal

David Fox

Sharon Malka

Eric Shem-Tov

Samuel Moed

John C. Lantis

Patients' Stories and Physicians' Experience

Lee-Anne Jones

Prof. Dr. Jan Plock & Dr. Frank Sander

We are interested in motivated and talented scientists, clinicians and healthcare professionals that are seeking a dynamic, collaborative work environment.

Innovation Powers Us Better Care Drives Us

Committed to Innovation Dedicated to Improving Patients' Lives

Our People. Our Values. Our Culture

A Fully-Integrated Biopharmaceutical Company

RESEARCH & DEVELOPMENT

MANUFACTURING

Commercialization

Our People: Leading Change

Ofer Gonen

Robert J. Snyder

Lior Rosenberg

Ety Klinger

Tzvi Palash

Boaz Gur-Lavie

Yaron Meyer

Andrey Kon

Keren David-Zarbiv

Roni Solomon

Eilon Asculai

Smadar Nestor

Nimrod Leuw

Nachum (Homi) Shamir

Stephen T. Wills

Vickie R Driver

Sharon Kochan

Nissim Mashiach

Assaf Segal

David Fox

Sharon Malka

Eric Shem-Tov

Samuel Moed

John C. Lantis

Patients' Stories and Physicians' Experience

Lee-Anne Jones

Prof. Dr. Jan Plock & Dr. Frank Sander

We are interested in motivated and talented scientists, clinicians and healthcare professionals that are seeking a dynamic, collaborative work environment.

Ofer Gonen

Robert J. Snyder

Lior Rosenberg

Ety Klinger

Tzvi Palash

Boaz Gur-Lavie

Yaron Meyer

Andrey Kon

Keren David-Zarbiv

Roni Solomon

Eilon Asculai

Smadar Nestor

Nimrod Leuw

Nachum (Homi) Shamir

Stephen T. Wills

Vickie R Driver

Sharon Kochan

Nissim Mashiach

Assaf Segal

David Fox

Sharon Malka

Eric Shem-Tov

Samuel Moed

John C. Lantis

Innovation Powers Us
Better Care Drives Us

Committed to Innovation
Dedicated to Improving Patients' Lives